Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

Running, not enrolling · Phase 2

Conditions studied: Breast Cancer

In brief

This is a randomized two arm phase II study to further evaluate the efficacy of fulvestrant plus enza compared to single agent fulvestrant in postmenopausal women with locally advanced AR+/ER+/Her2- BC who will have local surgery after \~4 months on treatment.

Key facts

Study ID

NCT02955394

Run by

University of Colorado, Denver

People needed

61

Starts

2017-09-21

Expected to finish

2027-02-01

Last updated by the study team

2025-07-09

Who can join

Age: 18 and older, up to 101. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• ER+ Her2- breast cancer
• Stage at least T2 or greater
• Planned to get local surgery
• Postmenopausal, or if pre- or peri- menopausal, then will need to have concurrent ovarian suppression.
• At least 18 years of age
• Not on anticoagulants
• PS 0-2
• Able to swallow study drug and comply with study requirements
• ANC >1000/uL, platelets >75,000/uL at screening visit
• Total bilirubin < 1.5 times upper limit of normal (ULN) at the screening visit unless an alternate nonmalignant etiology exists (eg, Gilbert's disease)
• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 times ULN or < 5 times ULN if patient has documented liver metastases
• Creatinine < 1.5 times ULN
• INR < 1.5 times ULN, or if on warfarin, can safely transition off for biopsy
• Willing to donate blood for research at 4 time points
• Willing to undergo core biopsies for research at study entry and at \~4 weeks.
• Willing to donate tissue to research from the surgical specimen
• Written informed consent obtained prior to biopsies and blood samples

You may not qualify if…

• Current or previously treated brain or leptomeningeal metastases
• History of seizures
• Prior treatment with an anti-androgen (abiraterone, ARN-509, bicalutamide, enzalutamide, ODM-201, TAK-448, TAK-683, TAK-700, VT-464).
• Systemic estrogens or androgens within 14 days before initiating therapy. Vaginal estrogens are allowed if necessary for patient comfort.

Where it is running

• University of Colorado — Aurora, Colorado, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• West Cancer Center — Germantown, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.